DS
BLCM

David Shaw’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

David Shaw’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,681
Closed -$151K – 4366
2019
Q4 		$151K Buy
11,681
+10,594
+975% +$97.8K ﹤0.01% 3840
2019
Q3 		$11K Buy
+1,087
New +$14.2K ﹤0.01% 3764
2017
Q4 		– Sell
-2,929
Closed -$338K – 3794
2017
Q3 		$338K Buy
2,929
+59
+2% +$6.21K ﹤0.01% 3096
2017
Q2 		$335K Buy
+2,870
New +$356K ﹤0.01% 2991

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

David Shaw's BLCM Position: Q1 2020 in Review

David Shaw sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 11,681 shares — an estimated $151K sold.

David Shaw first reported a position in BLCM in Q2 2017 and held it in 4 quarters. The position peaked at $338K in Q3 2017. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

  • David Shaw reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • David Shaw sold 11,681 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $151K.
  • David Shaw first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2017 and held it in 4 quarters.
  • David Shaw's Bellicum Pharmaceuticals, Inc. position peaked at $338K in Q3 2017.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on D.E. Shaw & Co's 13F filing for Q1 2020, filed 15 May 2020.